Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine.
Kanokudom S, Assawakosri S, Suntronwong N, Chansaenroj J, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Yorsaeng R, Duangchinda T, Chantima W, Pakchotanon P, Srimuan D, Thatsanatorn T, Klinfueng S, Mongkolsapaya J, Sudhinaraset N, Wanlapakorn N, Honsawek S, Poovorawan Y. Kanokudom S, et al. Among authors: assawakosri s. Vaccine. 2022 Sep 16;40(39):5657-5663. doi: 10.1016/j.vaccine.2022.08.033. Epub 2022 Aug 22. Vaccine. 2022. PMID: 36031500 Free PMC article.
Positive impact of lockdown on COVID-19 outbreak in Thailand.
Dechsupa S, Assawakosri S, Phakham S, Honsawek S. Dechsupa S, et al. Among authors: assawakosri s. Travel Med Infect Dis. 2020 Jul-Aug;36:101802. doi: 10.1016/j.tmaid.2020.101802. Epub 2020 Jun 20. Travel Med Infect Dis. 2020. PMID: 32569811 Free PMC article. No abstract available.
Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults.
Yorsaeng R, Suntronwong N, Phowatthanasathian H, Assawakosri S, Kanokudom S, Thongmee T, Vichaiwattana P, Auphimai C, Wongsrisang L, Srimuan D, Thatsanatorn T, Klinfueng S, Sudhinaraset N, Wanlapakorn N, Poovorawan Y. Yorsaeng R, et al. Among authors: assawakosri s. Vaccine. 2022 Jan 24;40(3):524-530. doi: 10.1016/j.vaccine.2021.11.083. Epub 2021 Dec 3. Vaccine. 2022. PMID: 34893344 Free PMC article.
Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine.
Kanokudom S, Assawakosri S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Yorsaeng R, Srimuan D, Thatsanatorn T, Klinfueng S, Sudhinaraset N, Wanlapakorn N, Honsawek S, Poovorawan Y. Kanokudom S, et al. Among authors: assawakosri s. Vaccines (Basel). 2022 Jan 6;10(1):86. doi: 10.3390/vaccines10010086. Vaccines (Basel). 2022. PMID: 35062747 Free PMC article.
Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study.
Wanlapakorn N, Suntronwong N, Phowatthanasathian H, Yorsaeng R, Vichaiwattana P, Thongmee T, Auphimai C, Srimuan D, Thatsanatorn T, Assawakosri S, Kanokudom S, Poovorawan Y. Wanlapakorn N, et al. Among authors: assawakosri s. Hum Vaccin Immunother. 2022 Dec 31;18(1):2029111. doi: 10.1080/21645515.2022.2029111. Epub 2022 Feb 24. Hum Vaccin Immunother. 2022. PMID: 35209809 Free PMC article.
Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
Assawakosri S, Kanokudom S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Duangchinda T, Chantima W, Pakchotanon P, Srimuan D, Thatsanatorn T, Klinfueng S, Yorsaeng R, Sudhinaraset N, Wanlapakorn N, Mongkolsapaya J, Honsawek S, Poovorawan Y. Assawakosri S, et al. J Infect Dis. 2022 Oct 17;226(8):1372-1381. doi: 10.1093/infdis/jiac092. J Infect Dis. 2022. PMID: 35267040
COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron.
Suntronwong N, Yorsaeng R, Puenpa J, Auphimai C, Thongmee T, Vichaiwattana P, Kanokudom S, Duangchinda T, Chantima W, Pakchotanon P, Assawakosri S, Nilyanimit P, Klinfueng S, Wongsrisang L, Srimuan D, Thatsanatorn T, Sudhinaraset N, Wanlapakorn N, Poovorawan Y. Suntronwong N, et al. Among authors: assawakosri s. Vaccines (Basel). 2022 Mar 3;10(3):391. doi: 10.3390/vaccines10030391. Vaccines (Basel). 2022. PMID: 35335023 Free PMC article.
Omicron BA.1, BA.2 and COVID-19 Booster Vaccination.
Assawakosri S, Kanokudom S, Suntronwong N, Puenpa J, Duangchinda T, Chantima W, Pakchotanon P, Mongkolsapaya J, Wanlapakorn N, Honsawek S, Poovorawan Y. Assawakosri S, et al. J Infect Dis. 2022 Oct 17;226(8):1480-1481. doi: 10.1093/infdis/jiac158. J Infect Dis. 2022. PMID: 35481828 Free PMC article. No abstract available.
Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination.
Assawakosri S, Kanokudom S, Chansaenroj J, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Duangchinda T, Chantima W, Pakchotanon P, Srimuan D, Thatsanatorn T, Klinfueng S, Sudhinaraset N, Mongkolsapaya J, Wanlapakorn N, Honsawek S, Poovorawan Y. Assawakosri S, et al. Int J Infect Dis. 2022 Sep;122:793-801. doi: 10.1016/j.ijid.2022.07.038. Epub 2022 Jul 19. Int J Infect Dis. 2022. PMID: 35863731 Free PMC article.
25 results